Compound LawsREAL-TIME LEGAL INTELLIGENCE
Home / Compounds / MGM-15 (dihydro-7-hydroxymitragynine) / Federal

MGM-15 (dihydro-7-hydroxymitragynine): Federal Status (2026)

Watchnotice of intent by the DEA (Drug Enforcement Administration), applies to every seller
Federally scheduled or prohibited

Federal Schedule I (DEA temporary order, drug code 9673), effective 2026-08-26 to 2028-08-26

Verified November 3, 2026

Federal status: MGM-15 (dihydro-7-hydroxymitragynine) is a Schedule I controlled substance under federal law by DEA temporary scheduling order under 21 U.S.C. 811(h), FR Doc. 2026-17429, 91 FR 54948 (Docket No. DEA-1644), effective 2026-08-26 until 2028-08-26, which added 21 CFR 1308.11(h)(90) with DEA drug code 9673; MGM-16 (9674) and mitragynine pseudoindoxyl (9672) were placed by the same order. The eCFR text of 21 CFR 1308.11, up to date as of 2026-10-26, carries paragraph (h)(90) with drug code 9673. On 2026-10-14 DEA published FR Doc. 2026-20942 (91 FR 65381), a notice of intent to issue a new temporary scheduling order for MGM-15 and MGM-16 that maintains their temporary schedule I placement without change; it states the new order will not be issued before 2026-11-13, that the 2026-08-26 order remains in effect until it expires or the new order is published and the previous order is withdrawn, and that the new order will run two years from its publication with a possible one-year extension. The notice was issued to separate MGM-15 and MGM-16 from mitragynine pseudoindoxyl after an HHS letter of 2026-10-06 that addressed a threshold for mitragynine pseudoindoxyl only. Effect: no gap in control; when the replacement order publishes, the controlling instrument and the sunset date move to that order. DEA states it intends to pursue permanent scheduling by formal rulemaking under 21 U.S.C. 811(a); no permanent rule, permanent-control NPRM, extension, or hearing notice for MGM-15 or MGM-16 was found in the Federal Register as of 2026-10-28. Every state row renders under this federal overlay: a state 'legal' or 'restricted' reports state law only and never implies federal lawfulness.

The Drug Enforcement Administration (DEA) is issuing this temporary order to schedule three 7-hydroxymitragynine-related substances (mitragynine pseudoindoxyl, MGM-15, and MGM-16), including their isomers, esters, ethers, salts, and salts of isomers, esters, and ethers, whenever the existence of such isomers, esters, ethers, and salts is possible, in schedule I of the Controlled Substances Act.

Citations

  1. Schedules of Controlled Substances: Temporary Placement of Mitragynine Pseudoindoxyl, MGM-15, and MGM-16 in Schedule I (temporary scheduling order, FR Doc. 2026-17429, 91 FR 54948, Docket No. DEA-1644) (Drug Enforcement Administration / Federal Register, 2026-10-28) PRIMARYOFFICIAL
  2. 21 CFR 1308.11(h)(90) (temporary, 91 FR 54948) PRIMARYOFFICIAL
  3. 21 CFR 1308.11 Schedule I (eCFR, current) (eCFR / Office of the Federal Register, 2026-10-28)OFFICIAL
  4. Schedules of Controlled Substances: Temporary Placement of MGM-15 and MGM-16 in Schedule I (notice of intent, FR Doc. 2026-20942, 91 FR 65381, Docket No. DEA-1644) (Drug Enforcement Administration / Federal Register, 2026-10-28)OFFICIAL
  5. 21 U.S.C. 811(h) Temporary scheduling to avoid imminent hazards to public safety (Office of the Law Revision Counsel, U.S. House of Representatives, 2026-10-28)OFFICIAL
  6. Schedules of Controlled Substances: Temporary Placement of Mitragynine Pseudoindoxyl, MGM-15, and MGM-16 in Schedule I (notice of intent, FR Doc. 2026-13581, 91 FR 40909, Docket No. DEA-1644) (Drug Enforcement Administration / Federal Register, 2026-10-28)OFFICIAL
  7. Hiding in Plain Sight: 7-OH Products (FDA public health focus page) (U.S. Food and Drug Administration, 2026-10-28)OFFICIAL

Federal instruments on file

21 CFR 1308.11(h)(89)-(91) (temporary, 91 FR 54948) · Temporary placement of mitragynine pseudoindoxyl, MGM-15 and MGM-16 in Schedule I - amendatory textOFFICIAL
Instrument
Temporary placement of mitragynine pseudoindoxyl, MGM-15 and MGM-16 in Schedule I - amendatory text
Source
https://www.federalregister.gov/documents/2026/08/26/2026-17429/schedules-of-controlled-substances-temporary-placement-of-mitragynine-pseudoindoxyl-mgm-15-and
Retrieved
2026-09-22
Fingerprint
fa16cebdc1144cd6
For the reasons set out above, DEA amends 21 CFR part 1308 as 
follows:
PART 1308--SCHEDULES OF CONTROLLED SUBSTANCES
0
1. The authority citation for part 1308 continues to read as follows:
 Authority: 21 U.S.C. 811, 812, 871(b), 956(b), unless otherwise 
noted.
0
2. In Sec. 1308.11, add paragraphs (h)(89) through (91) to read as 
follows:
Sec. 1308.11 Schedule I.
* * * * *
 (h) * * *
------------------------------------------------------------------------
 * * * * * * *
(89) Methyl (E)-2-((1'S,6'S,7'S)-6'-ethyl-4-methoxy-3-oxo- 9672
 3',5',6',7',8',8a'-hexahydro-2'H-spiro[indoline-2,1'-
 indolizine]-7'-yl)-3-methoxyacrylate (commonly known as
 mitragynine pseudoindoxyl) including its isomers, esters,
 ethers, salts, and salts of isomers, esters, and ethers,
 whenever the existence of such isomers, esters, ethers, and
 salts is possible. Since nomenclature of this substance is not
 internationally standardized, compounds of this structure,
 regardless of numerical designation of atomic positions are
 covered
(90) Methyl (E)-2-((2S,3S,7aS,12aR,12bS)-3-ethyl-7a-hydroxy-8- 9673
 methoxy-1,2,3,4,6,7,7a,12,12a,12b-decahydroindolo[2,3-
 a]quinolizin-2-yl)-3-methoxyacrylate (commonly known as MGM-
 15; also known as dihydro-7-hydroxymitragynine) including its
 isomers, esters, ethers, salts, and salts of isomers, esters,
 and ethers, whenever the existence of such isomers, esters,
 ethers, and salts is possible. Since nomenclature of this
 substance is not internationally standardized, compounds of
 this structure, regardless of numerical designation of atomic
 positions are covered
(91) Methyl (E)-2-((2S,3S,7aS,12aR,12bS)-3-ethyl-9-fluoro-7a- 9674
 hydroxy-8- methoxy-1,2,3,4,6,7,7a,12,12a,12b-
 decahydroindolo[2,3-a]quinolizin-2-yl)-3-methoxyacrylate
 (commonly known as MGM-16; also known as 9-fluoro-dihydro-7-
 hydroxymitragynine; or 10-fluoro-dihydro-7-hydroxymitragynine
 (depending on numbering convention)) including its isomers,
 esters, ethers, salts, and salts of isomers, esters, and
 ethers, whenever the existence of such isomers, esters,
 ethers, and salts is possible. Since nomenclature of this
 substance is not internationally standardized, compounds of
 this structure, regardless of numerical designation of atomic
 positions are covered
------------------------------------------------------------------------
21 CFR 1308.11(h)(90) (temporary, 91 FR 54948) · Schedule I temporary listing, MGM-15 (dihydro-7-hydroxymitragynine) (drug code 9673), amendatory text of FR Doc. 2026-17429OFFICIAL
Instrument
Schedule I temporary listing, MGM-15 (dihydro-7-hydroxymitragynine) (drug code 9673), amendatory text of FR Doc. 2026-17429
Source
https://www.federalregister.gov/documents/full_text/text/2026/08/26/2026-17429.txt
Retrieved
2026-10-28
Fingerprint
753842c4cd890452
(90) Methyl (E)-2-((2S,3S,7aS,12aR,12bS)-3-ethyl-7a-hydroxy-8-      9673
 methoxy-1,2,3,4,6,7,7a,12,12a,12b-decahydroindolo[2,3-
 a]quinolizin-2-yl)-3-methoxyacrylate (commonly known as MGM-
 15; also known as dihydro-7-hydroxymitragynine) including its
 isomers, esters, ethers, salts, and salts of isomers, esters,
 and ethers, whenever the existence of such isomers, esters,
 ethers, and salts is possible. Since nomenclature of this
 substance is not internationally standardized, compounds of
 this structure, regardless of numerical designation of atomic
 positions are covered
21 CFR 1308.11(h)(91) (temporary, 91 FR 54948) · Schedule I temporary listing, MGM-16 (9-fluoro-dihydro-7-hydroxymitragynine; 10-fluoro under an alternate numbering) (drug code 9674), amendatory text of FR Doc. 2026-17429OFFICIAL
Instrument
Schedule I temporary listing, MGM-16 (9-fluoro-dihydro-7-hydroxymitragynine; 10-fluoro under an alternate numbering) (drug code 9674), amendatory text of FR Doc. 2026-17429
Source
https://www.federalregister.gov/documents/full_text/text/2026/08/26/2026-17429.txt
Retrieved
2026-10-28
Fingerprint
78d1ca95da6494c6
(91) Methyl (E)-2-((2S,3S,7aS,12aR,12bS)-3-ethyl-9-fluoro-7a-       9674
 hydroxy-8- methoxy-1,2,3,4,6,7,7a,12,12a,12b-
 decahydroindolo[2,3-a]quinolizin-2-yl)-3-methoxyacrylate
 (commonly known as MGM-16; also known as 9-fluoro-dihydro-7-
 hydroxymitragynine; or 10-fluoro-dihydro-7-hydroxymitragynine
 (depending on numbering convention)) including its isomers,
 esters, ethers, salts, and salts of isomers, esters, and
 ethers, whenever the existence of such isomers, esters,
 ethers, and salts is possible. Since nomenclature of this
 substance is not internationally standardized, compounds of
 this structure, regardless of numerical designation of atomic
 positions are covered
21 U.S.C. 802(32) and 21 U.S.C. 813(a) · Controlled substance analogue (definition and treatment)OFFICIAL
Instrument
Controlled substance analogue (definition and treatment)
Source
https://www.govinfo.gov/content/pkg/USCODE-2023-title21/html/USCODE-2023-title21-chap13-subchapI-partA-sec802.htm
Retrieved
2026-11-08
Fingerprint
4d9abc695447adae
(32)(A) Except as provided in subparagraph (C), the term "controlled substance analogue" means a substance—

(i) the chemical structure of which is substantially similar to the chemical structure of a controlled substance in schedule I or II;

(ii) which has a stimulant, depressant, or hallucinogenic effect on the central nervous system that is substantially similar to or greater than the stimulant, depressant, or hallucinogenic effect on the central nervous system of a controlled substance in schedule I or II; or

(iii) with respect to a particular person, which such person represents or intends to have a stimulant, depressant, or hallucinogenic effect on the central nervous system that is substantially similar to or greater than the stimulant, depressant, or hallucinogenic effect on the central nervous system of a controlled substance in schedule I or II.

(B) The designation of gamma butyrolactone or any other chemical as a listed chemical pursuant to paragraph (34) or (35) does not preclude a finding pursuant to subparagraph (A) of this paragraph that the chemical is a controlled substance analogue.

(C) Such term does not include—

(i) a controlled substance;

(ii) any substance for which there is an approved new drug application;

(iii) with respect to a particular person any substance, if an exemption is in effect for investigational use, for that person, under section 355 of this title to the extent conduct with respect to such substance is pursuant to such exemption; or

(iv) any substance to the extent not intended for human consumption before such an exemption takes effect with respect to that substance.

(a) In general

A controlled substance analogue shall, to the extent intended for human consumption, be treated, for the purposes of any Federal law as a controlled substance in schedule I.

Related

MGM-15 (dihydro-7-hydroxymitragynine) by state · How federal precedence works · Temporary scheduling

Cite this page

Compound Analytics. “MGM-15 (dihydro-7-hydroxymitragynine): Federal Status (2026).” Compound Laws, https://compoundlaws.com/compounds/mgm-15/federal/. Accessed November 13, 2026.

Compound Laws, published by Compound Analytics, reports the record: statutes verbatim, official citations, enforcement facts and verification dates. Nothing here is legal advice and nothing here describes how to get around a law. A jurisdiction with no verified row is reported as not yet verified, never as legal. Found an error? Corrections policy.

About · Methodology · Glossary · Changes · RSS · Data licensing · llms.txt · Sitemap